Immuneering Corp Begin Period Cash Flow Over Time
| IMRX Stock | USD 2.06 0.07 3.29% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Immuneering Corp Performance and Immuneering Corp Correlation. Immuneering |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immuneering Corp. If investors know Immuneering will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immuneering Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.97) | Quarterly Revenue Growth (1.00) | Return On Assets (0.37) | Return On Equity (0.62) |
The market value of Immuneering Corp is measured differently than its book value, which is the value of Immuneering that is recorded on the company's balance sheet. Investors also form their own opinion of Immuneering Corp's value that differs from its market value or its book value, called intrinsic value, which is Immuneering Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immuneering Corp's market value can be influenced by many factors that don't directly affect Immuneering Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Immuneering Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Immuneering Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immuneering Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Begin Period Cash Flow Analysis
Compare Immuneering Corp and related stocks such as Theseus Pharmaceuticals, Pmv Pharmaceuticals, and Cullinan Oncology LLC Begin Period Cash Flow Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PMVP | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 23.8 M | 30.3 M | 73.3 M | 361.4 M | 173.3 M | 109.1 M | 141.4 M |
| CGEM | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 33.8 M | 63.2 M | 168.2 M | 59.8 M | 156.2 M | 97 M |
| ELVN | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 7.5 M | 9.7 M | 7.4 M | 8.9 M | 130.4 M | 110.1 M | 75.6 M | 54.9 M |
| LRMR | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 35.5 M | 58.1 M | 35.6 M | 32.4 M | 40.8 M | 4.4 M | 1 M | 69.5 M | 71.4 M | 26.8 M | 41.3 M |
| CNTA | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 12.9 M | 16.6 M | 5 M | 595.1 M | 393.6 M | 225.1 M |
| CELC | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 2.3 M | 5.1 M | 5.9 M | 2.7 M | 15.9 M | 18.7 M | 11.6 M | 84.3 M | 24.6 M | 20.9 M |
| IKNA | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 18.2 M | 82.1 M | 163.4 M | 233.1 M | 60.8 M | 57.8 M |
| REPL | 14.4 M | 14.4 M | 14.4 M | 14.4 M | 14.4 M | 14.4 M | 14.4 M | 20.7 M | 17.7 M | 26.9 M | 61.1 M | 184.2 M | 107.6 M | 148.2 M | 79.9 M |
| NVCT | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 7.2 M | 5.7 M | 20 M | 12.1 M |
| LYRA | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 24.2 M | 10.1 M | 74.9 M | 46.1 M | 33.9 M | 35 M |
| KRON | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 1.5 M | 10.2 M | 32.6 M | 250 M | 200.3 M | 78 M | 105 M |
| GOSS | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 60 K | 315 K | 105.4 M | 135.1 M | 486.6 M | 183.5 M | 112 M | 140.7 M |
| GLUE | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 1.8 M | 9.2 M | 42.9 M | 351.4 M | 60.2 M | 102.4 M |
| NAMS | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 2.5 M | 7.9 M | 53.1 M | 467.7 M | 491.1 M |
| IVA | 10.9 M | 10.9 M | 10.9 M | 10.9 M | 13.5 M | 17.1 M | 22.6 M | 24.9 M | 59.1 M | 56.7 M | 35.8 M | 105.7 M | 86.6 M | 86.7 M | 52 M |
| CMPX | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 29.4 M | 57.8 M | 25.6 M | 47.3 M | 144.5 M | 34.9 M | 62.3 M |
Immuneering Corp and related stocks such as Theseus Pharmaceuticals, Pmv Pharmaceuticals, and Cullinan Oncology LLC Begin Period Cash Flow description
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.My Equities
My Current Equities and Potential Positions
| Immuneering Corp | IMRX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.06
Additional Tools for Immuneering Stock Analysis
When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.